MX9700308A - Derivados heterobiciclicos. - Google Patents

Derivados heterobiciclicos.

Info

Publication number
MX9700308A
MX9700308A MX9700308A MX9700308A MX9700308A MX 9700308 A MX9700308 A MX 9700308A MX 9700308 A MX9700308 A MX 9700308A MX 9700308 A MX9700308 A MX 9700308A MX 9700308 A MX9700308 A MX 9700308A
Authority
MX
Mexico
Prior art keywords
alkyl
suitable substituent
heterobicyclic derivatives
aryl
heterocyclic group
Prior art date
Application number
MX9700308A
Other languages
English (en)
Inventor
Norihiko Shimazaki
Shinya Watanabe
Akihiko Sawada
Hemmi Keiji
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of MX9700308A publication Critical patent/MX9700308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Derivados heterobicíclicos de la formula (I), en la que R1 es arilo el cual puede tener substituyentes adecuados, aralquilo inferior el cual puede tener substituyentes adecuados, haloalquilo inferior, carboxialquilo inferior protegido, acilalquilo inferior, un grupo heterocíclico o heterociclilalquilo inferior el cual puede tener substituyentes adecuados, R2 es arilo el cual puede tener substituyentes adecuados o un grupo heterocíclico, y R3 es hidrogeno alcoxi inferior o ariltio, y una sal farmacéuticamente aceptable del mismo, los cuales son utiles como un medicamento.
MX9700308A 1994-07-11 1995-07-10 Derivados heterobiciclicos. MX9700308A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9413975A GB9413975D0 (en) 1994-07-11 1994-07-11 New heterobicyclic derivatives
PCT/JP1995/001366 WO1996001825A1 (en) 1994-07-11 1995-07-10 Heterobicyclic derivatives

Publications (1)

Publication Number Publication Date
MX9700308A true MX9700308A (es) 1997-05-31

Family

ID=10758154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700308A MX9700308A (es) 1994-07-11 1995-07-10 Derivados heterobiciclicos.

Country Status (19)

Country Link
US (2) US6426345B1 (es)
EP (2) EP0770079B1 (es)
JP (1) JP3206003B2 (es)
KR (1) KR100394761B1 (es)
CN (2) CN1051548C (es)
AT (1) ATE232531T1 (es)
AU (1) AU698133B2 (es)
CA (1) CA2194872A1 (es)
DE (1) DE69529614T2 (es)
DK (1) DK0770079T3 (es)
ES (1) ES2187561T3 (es)
GB (1) GB9413975D0 (es)
HK (1) HK1004483A1 (es)
HU (1) HUT77353A (es)
MX (1) MX9700308A (es)
PT (1) PT770079E (es)
RU (2) RU2170737C2 (es)
TW (1) TW383307B (es)
WO (1) WO1996001825A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
DE19710609A1 (de) 1997-03-14 1998-09-17 Bayer Ag Substituierte Aminosalicylsäureamide
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
CN1328555A (zh) * 1998-09-29 2001-12-26 藤泽药品工业株式会社 吡啶并吡嗪化合物的新的盐及其结晶
JP2002539187A (ja) * 1999-03-17 2002-11-19 アストラゼネカ アクチボラグ アミド誘導体
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
ATE362926T1 (de) 2000-01-20 2007-06-15 Eisai R&D Man Co Ltd Stickstoffhaltige cyclische verbindungen und sie enthaltende pharmazeutische zubereitungen
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP5025057B2 (ja) * 2001-05-10 2012-09-12 株式会社半導体エネルギー研究所 半導体装置の作製方法
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
KR100490970B1 (ko) * 2002-03-22 2005-05-24 씨제이 주식회사 신규 피리도[2,3-ｄ]피리미딘 카르보알데히드 옥심계ＰＤＥ Ⅳ 효소 저해 화합물 및 이의 제조방법
PT1525200E (pt) * 2002-08-02 2008-01-10 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CA2497192A1 (en) * 2002-09-16 2004-03-25 Alcon Manufacturing, Ltd. Use of pde iv inhibitors to treat angiogenesis
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004209456A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid VR1 receptor
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
PT1636228E (pt) * 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
WO2006126081A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) * 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
HUE033849T2 (en) * 2008-03-05 2018-01-29 Merck Patent Gmbh Pyridopyrazinone derivative for insulin secretagogues, methods for their preparation and their use in the treatment of diabetes
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
CN104739820B (zh) * 2014-09-30 2017-02-15 三峡大学 一种小分子抑制剂及在抑制鸟氨酸脱羧酶上的应用
US20170314007A1 (en) * 2014-09-30 2017-11-02 China Three Gorges University Medicament design pocket of ornithine decarboxylase and application of medicament design pocket
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
ZA794209B (en) * 1978-08-15 1980-07-30 Fisons Ltd Pharmaceutically active heterocyclic compounds
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives

Also Published As

Publication number Publication date
CN1051548C (zh) 2000-04-19
HU9700068D0 (en) 1997-02-28
DE69529614D1 (de) 2003-03-20
AU2899295A (en) 1996-02-09
RU2170737C2 (ru) 2001-07-20
GB9413975D0 (en) 1994-08-31
CN1250776A (zh) 2000-04-19
WO1996001825A1 (en) 1996-01-25
RU2001107897A (ru) 2003-01-20
DK0770079T3 (da) 2003-06-10
KR100394761B1 (ko) 2003-11-20
TW383307B (en) 2000-03-01
PT770079E (pt) 2003-06-30
DE69529614T2 (de) 2003-07-03
ATE232531T1 (de) 2003-02-15
AU698133B2 (en) 1998-10-22
US6426345B1 (en) 2002-07-30
US20020107251A1 (en) 2002-08-08
HUT77353A (hu) 1998-03-30
EP0920867A1 (en) 1999-06-09
ES2187561T3 (es) 2003-06-16
CN1157617A (zh) 1997-08-20
JPH10502630A (ja) 1998-03-10
EP0770079A1 (en) 1997-05-02
JP3206003B2 (ja) 2001-09-04
HK1004483A1 (en) 1998-11-27
US6727245B2 (en) 2004-04-27
CA2194872A1 (en) 1996-01-25
EP0770079B1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
MX9700308A (es) Derivados heterobiciclicos.
MX9800577A (es) Derivados de 4,5-diaril oxazol.
KR960701055A (ko) 인터로이킨-1 및 종양 괴사 인자 억제 활성을 지닌 피라졸로트리아진 (pyrazol itriazines with interleukin-1 and tumour necrosis factor in-hibitory actvity)
DE60003001D1 (en) Pyrimidinverbindungen
ZA200206191B (en) Pyrimidine compounds.
CA2547947A1 (en) Azole derivatives as active superoxide radical inhibitors
AU1200695A (en) 4,5-diaryloxazole derivatives
BG104112A (en) 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them
WO1996004241A3 (en) Benzoylguanidine derivatives as medicaments
IL108258A0 (en) Piperazine derivates, their preparation and pharmaceutical compositions containing them
AU6731100A (en) Integrase inhibitors containing aromatic heterocycle derivatives
TW200407315A (en) Pyrimidine derivatives
HK1005732A1 (en) Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
IL147307A0 (en) Indolocarbazole alkaloid derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof